Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rozanolixizumab in generalized myasthenia gravis
jRCT2021200038Completed
- Sponsor
- UCB
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of rozanolixizumab in myasthenia gravis (MG) (2 arms), sponsored by UCB. Primary endpoints: Percentage of participants with treatment-emergent adverse events and Percentage of participants with TEAEs leading to permanent withdrawal of investigational medicinal product. Started Feb 2021; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021200038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021200038.